You are here: Home » 0 » » Archives for 0st

Centrient Pharmaceuticals announces its achievement of a significant milestone in the clean production of antibiotics

Rijswijk, The Netherlands, May 19, 2022 (GLOBE NEWSWIRE) —

Summary

  • Centrient Pharmaceuticals reached a significant milestone in the clean production of its antibiotics, with the lowest environmental impact and minimizing the potential contribution to antimicrobial resistance
  • The company is the first to publicly announce that Its entire supply chain of oral antibiotics "" including its own and supplier manufacturing sites – is fully compliant with the stringent Predicted No Effect Concentration (PNEC) discharge targets set by the AMR Industry Alliance
  • This achievement demonstrates Centrient Pharmaceuticals' commitment and leadership in the responsible production of antibiotics.

Centrient Pharmaceuticals announces 100% compliance with the stringent Predicted No Effect Concentration (PNEC) discharge targets set by the AMR Industry Alliance for clean manufacturing of its full oral antibiotics product range. This standard covers both Centrient's sites and its suppliers' sites. This achievement positions the company as a frontrunner in the industry with the delivery of responsibly–produced antibiotics, which minimize the possible contribution to antimicrobial resistance.

The PNEC discharge target is the concentration of an antibiotic in water at which there is unlikely to be a risk of adverse environmental effects or of antimicrobial resistance (AMR) developing. These scientific, risk–based targets were developed by the AMR Industry Alliance and cover around 120 active pharmaceutical ingredients (APIs) used in antibiotic manufacturing. Each individual antibiotic has a corresponding PNEC value, published in the AMR Industry Alliance table of Recommended PNECs for Risk Assessments (updated periodically).

High concentrations of antibiotic residues in factory wastewater can create hotspots of resistant bacteria which may lead to AMR. While manufacturing is just one of the contributors to the emergence of AMR in the environment, its impact cannot be overlooked. AMR is a major threat to global public health as well as to the healthcare industry. Many standard medical procedures such as organ transplants, chemotherapy, and surgeries such as caesarean sections become much more dangerous without effective antibiotics to prevent and treat infections. Antibiotics are the cornerstone of our modern healthcare system, and complying with PNEC standards enables manufacturers to ensure supply of these critically important medicines does not contribute to the risk of AMR.

The PNEC values are increasingly being recognized as the standard for antibiotic discharge concentrations in water and are expanding beyond Alliance companies and their supply chains. For example, tenders in the UK and Germany (health insurer AOK) include a specific reference to the PNEC discharge targets. Also, companies assessed externally by organizations such as the Access to Medicine Foundation will have public exposure for their performance on PNECs.

As a strong advocate for sustainable manufacturing, Centrient Pharmaceuticals became a founding board member of the AMR Industry Alliance in 2017, working with partners to raise awareness and deliver solutions to the AMR issue. Since then, the company's own journey to reaching full compliance has included establishing state–of–the–art wastewater treatment facilities at all their sites worldwide and developing tests for measuring antibiotic activity in wastewater streams, leading to a fully clean and PNEC–compliant supply chain.

"We are proud to be the first in our industry to publicly announce PNEC compliance for our oral antibiotics product supply chain.

At Centrient Pharmaceuticals, our commitment to Sustainability is in our DNA "" we ensure that the way in which we produce pharmaceuticals has the lowest environmental impact and does not contribute to AMR. We are proud of our PureActives enzymatic low–carbon technology, ISO 14001 certification of all our sites, and Board positions at the Pharmaceutical Supply Chain Initiative and AMR Industry Alliance.

We will continue to work with customers, suppliers, industry and government decision–makers across the value chain to make the supply and buying of antibiotics sustainable to curb AMR.", says Rex Clements, CEO at Centrient Pharmaceuticals.

Read our whitepaper "Manufacturing sustainable antibiotics for the future' here.

—————————————————————————————————————————————————————————————–


About Centrient Pharmaceuticals

Centrient Pharmaceuticals is the global leader in the production and commercialisation of sustainable antibiotics, next–generation statins, and anti–fungals. We produce and sell intermediates, active pharmaceutical ingredients and finished dosage forms.

We stand proudly at the centre of modern healthcare, as a maker of essential and life–saving medicines. With our commitment to Quality, Reliability and Sustainability at the heart of everything we do, our over 2,200 employees work continuously to meet our customers' needs. We work towards a sustainable future by actively participating in the fight against antimicrobial resistance.

Founded 150 years ago as the "Nederlandsche Gist– en Spiritusfabriek', our company was known as Gist Brocades and more recently DSM Sinochem Pharmaceuticals. Headquartered in Rijswijk (Netherlands), we have production facilities and sales offices in China, India, the Netherlands, Spain, the United States and Mexico. Centrient Pharmaceuticals is wholly owned by Bain Capital Private Equity, a leading global private investment firm.

For more information please visit www.centrient.com or contact Centrient Pharmaceuticals Corporate Communications, Alice Beijersbergen, Director Branding & Communications. E–Mail: alice.beijersbergen@centrient.com.

About the AMR Industry Alliance

The AMR Industry Alliance was formed in 2017. With approximately 100 life sciences companies and trade associations, it represents nearly one–third of the volume of sales and the majority of all novel products. Members have committed to report on activities they are undertaking in the areas of research & science, access to antibiotics and appropriate use of these, as well as responsible environmental manufacturing to tackle the rapid spread of antimicrobial resistance. If AMR remains unchecked, the annual death toll could climb from 700,000 each year to 10 million by 2050 and the economic impacts could be on par with those of the 2008 financial crisis. The AMR Industry Alliance ensures that signatories collectively deliver on the specific commitments made in the Industry Declaration on AMR and the Roadmap for Progress on Combating AMR and measures progress made in the fight against AMR.

Forward–looking statements

This press release may contain forward–looking statements with respect to Centrient Pharmaceuticals' future financial performance and position. Such statements are based on current expectations, estimates and projections of Centrient and information currently available to the company. Centrient cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. Centrient has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is governing.


GLOBENEWSWIRE (Distribution ID 8545387)

Mainz Biomed & Dante Labs Announce Partnership for the Commercialization of ColoAlert in Europe and the United Arab Emirates (UAE)

  • Dante Labs is a Global Leader in Genomics and Precision Medicine
  • Mainz is Exclusively Focused on Developing Next Generation Diagnostics for the Early Detection of Cancer

BERKELEY, Calif. and MAINZ, Germany and NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer and Dante Labs, a global leader in genomics and precision medicine, announced today a partnership for the commercialization of ColoAlert in Italy and the United Arab Emirates (UAE). ColoAlert is Mainz's flagship product, a highly efficacious and easy to use at–home detection test for colorectal cancer (CRC).

Dante Labs is a global leader in genome sequencing with a product development and commercial franchise focused on providing personalized preventive healthcare solutions by leveraging its robust databases and proprietary software platform to offer next–generation diagnostic tools direct to consumers and healthcare professionals. Inherent to Dante Lab's business model is managing state–of–the–art genomic sequencing laboratories in multiple international regions, and operating a robust e–commerce platform.

"As a young company with the goal of bringing to market important diagnostic tools to help treat and prevent cancer indications, it's an absolute pleasure to partner with an industry leader such as Dante Labs," commented Guido Baechler, Chief Executive Officer of Mainz Biomed. "Our differentiated commercial plan of partnering with third–party laboratories for test kit processing versus the traditional methodology of operating a single facility requires alliances with like–minded companies such as Dante Labs, who share our passion for forward–thinking diagnostic test development and marketing strategies."

The partnership will first launch ColoAlert in Italy and UAE using Dante's various established commercial channels. Samples will initially be processed at Mainz's in–house facility and then Dante will purchase Mainz's CE–IVD polymerase chain reaction (PCR) assay kits and transition all test processing to Dante's wholly–owned automated genomic sequencing laboratories in Italy (Europe) and Dubai (UAE) to offer localized service and support.

"We are excited by the opportunity to align with Mainz and represent ColoAlert in these initial markets," commented Andrea Riposati, Chief Executive Officer of Dante Labs. "Both the product and the Company mirror our mission to develop and market top–tier preventive health solutions and use new channels to make innovative tests available to more patients around the world. With the launch of our enhanced ecommerce platforms for advanced diagnostics, ColoAlert is an amazing product to deliver more personalized medicine."

ColoAlert is currently marketed across Europe, and the partnership with Dante Labs marks the test's initial launch in the Middle East. Mainz will continue to develop commercial and R&D partnerships with companies that lead the field of health screening with a particular focus on stool diagnostics.

About ColoAlert

ColoAlert detects colorectal cancer (CRC) via a simple–to–administer test with a sensitivity and specificity nearly as high as the invasive colonoscopy*. The test utilizes proprietary methods to analyze cell DNA for specific tumor markers combined with the fecal immunochemical test (FIT) and is designed to detect tumor DNA and CRC cases in their earliest stages. The product is CE–IVD marked (complying with EU safety, health and environmental requirements) and is transitioning to compliance with IVDR. The product is commercially available in a selection of countries in the Europe Union. Mainz Biomed currently distributes ColoAlert through a number of clinical affiliates. Once approved in the U.S., the Company's commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country.

*Dollinger MM et al. (2018)

About Colorectal Cancer

Colorectal cancer (CRC) is the second most lethal cancer in the U.S. and Europe, but also the most preventable with early detection providing survival rates above 90%. Annual testing costs per patient are minimal, especially when compared to late–stage treatments of CRC which cost patients an average of $38,469 per year. The American Cancer Society estimated that in 2021 there were approximately 149,500 new cases of colon and rectal cancer in the U.S. with 52,980 resulting in death. Recent FDA decisions suggest that screening with stool DNA tests such as ColoAlert in the US should be conducted once every three years starting at age 45. Currently there are 112 million Americans aged 50+, a total that is expected to increase to 157 million within 10 years. Appropriately testing these US–based 50+ populations every three years as prescribed equates to a US market opportunity of approximately $3.7 Billion per year.

About Mainz Biomed N.V.

Mainz Biomed develops market–ready molecular genetic diagnostic solutions for life–threatening conditions. The Company's flagship product is ColoAlert, an accurate, non–invasive, and easy–to–use early detection diagnostic test for colorectal cancer. ColoAlert is currently marketed across Europe with FDA clinical study and submission process intended to be launched in the first half of 2022 for U.S. regulatory approval. Mainz Biomed's product candidate portfolio includes PancAlert, an early–stage pancreatic cancer screening test based on Real–Time Polymerase Chain Reaction–based (PCR) multiplex detection of molecular–genetic biomarkers in stool samples, and the GenoStick technology, a platform being developed to detect pathogens on a molecular genetic basis.

For more information please visit www.mainzbiomed.com

For media enquiries, please contact press@mainzbiomed.com

For investor enquiries, please contact ir@mainzbiomed.com

About Dante Labs
Dante Labs is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

Contact:

Laura D'Angelo
VP of Investor Relations
ir@dantelabs.com
+39 0862 191 0671
www.dantelabs.com

Forward–Looking Statements

Certain statements made in this press release are "forward–looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward–looking statements may be identified by the use of words such as "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward–looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward–looking statements. Due to known and unknown risks, actual results may differ materially from the Company's expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward–looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID–19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the "SEC") by the Company. Additional information concerning these and other factors that may impact the Company's expectations and projections can be found in its initial filings with the SEC, including its Prospectus filed on October 12, 2021 and amended on October 25, 2021 and November 1, 2021 as well as the Prospectus filed on January 21, 2022. The Company's SEC filings are available publicly on the SEC's website at www.sec.gov. Any forward–looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward–looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.


GLOBENEWSWIRE (Distribution ID 8545842)